AAVantgarde
Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease
70 employees · est. 2021
GenSight Biologics
Applying pathbreaking science to transform the lives of patients with severe retinal neurodegenerative diseases
34 employees · est. 2013 · Paris, France
GenSight Biologics is the older company (2021 vs 2013); AAVantgarde is the larger of the two.
Side-by-Side Comparison
| Metric | AAVantgarde | GenSight Biologics |
|---|---|---|
| Founded | ||
| Founded | 2021 | 2013 older |
| Headquarters | ||
| Headquarters | Not tracked yet | Paris, France |
| Employees | ||
| Employees | 70 larger | 34 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Series A | Post Ipo Equity |
| Total Funding | ||
| Total Funding | Not tracked yet | $245.64M |
| Funding Rounds | ||
| Funding Rounds | Not tracked yet | 17 |
| Services | ||
| Services | Developing Gene Therapies, Clinical Trial Advancement, Scientific Research and Development | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients with Inherited Retinal Disorders, Healthcare Providers, Ophthalmologists | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Gene Therapy, Inherited Retinal Diseases, Stargardt Disease, Usher Syndrome, AAVantgarde Bio, Clinical Stage Biotechnology, Translational Science, Ophthalmology, Rare Diseases, Retinal Disorders | Clinical-stage Biotech, Gene Therapy, Retinal Diseases, Neurodegenerative Diseases, Mitochondrial Targeting Sequence, Optogenetics, Retinitis Pigmentosa, LHON, Gene Therapy-Based Treatments, Intravitreal Injection, Vision Restoration, Retinal Degeneration, Rare Diseases, Innovative Therapies |
| Website | ||
| Website | aavantgarde.com | gensight-biologics.com |
About AAVantgarde
AAVantgarde, founded in 2021, is a promising entrant in the biotechnology space, targeting unmet needs in health care. This clinical-stage company is committed to pioneering treatments for Stargardt disease and Usher 1B, with a focus on addressing the root causes of these inherited retinal diseases...
About GenSight Biologics
GenSight Biologics is a biotechnology startup focused on developing groundbreaking therapies for severe retinal neurodegenerative diseases. Leveraging the Mitochondrial Targeting Sequence (MTS) and optogenetics, the company is striving to preserve or restore vision in patients with degenerative reti...
We will tell you when either one moves
BounceWatch watches AAVantgarde and GenSight Biologics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at AAVantgarde and GenSight Biologics — by email.
Frequently Asked Questions
Compare AAVantgarde with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at AAVantgarde on 28 Jan 2026, and GenSight Biologics on 11 Jun 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
